- Home
- SOR vs CADL Comparison
SOR vs CADL Comparison
Compare SOR & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- CADL
- Stock Information
- Founded
- SOR 1968
- CADL 1999
- Country
- SOR United States
- CADL United States
- Employees
- SOR N/A
- CADL N/A
- Industry
- SOR Investment Managers
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- CADL Health Care
- Exchange
- SOR Nasdaq
- CADL Nasdaq
- Market Cap
- SOR 368.0M
- CADL 339.8M
- IPO Year
- SOR N/A
- CADL 2021
- Fundamental
- Price
- SOR $45.66
- CADL $5.46
- Analyst Decision
- SOR
- CADL Strong Buy
- Analyst Count
- SOR 0
- CADL 7
- Target Price
- SOR N/A
- CADL $19.57
- AVG Volume (30 Days)
- SOR 16.2K
- CADL 828.2K
- Earning Date
- SOR 01-01-0001
- CADL 11-13-2025
- Dividend Yield
- SOR 7.24%
- CADL N/A
- EPS Growth
- SOR N/A
- CADL N/A
- EPS
- SOR 6.50
- CADL N/A
- Revenue
- SOR N/A
- CADL N/A
- Revenue This Year
- SOR N/A
- CADL N/A
- Revenue Next Year
- SOR N/A
- CADL N/A
- P/E Ratio
- SOR $6.41
- CADL N/A
- Revenue Growth
- SOR N/A
- CADL N/A
- 52 Week Low
- SOR $36.41
- CADL $3.79
- 52 Week High
- SOR $42.75
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- SOR 50.61
- CADL 48.28
- Support Level
- SOR $44.96
- CADL $5.35
- Resistance Level
- SOR $46.00
- CADL $5.80
- Average True Range (ATR)
- SOR 0.70
- CADL 0.35
- MACD
- SOR -0.03
- CADL -0.03
- Stochastic Oscillator
- SOR 36.59
- CADL 25.09
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.